China Rare Epilepsies Therapeutics market size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of 5.1% during the forecast period.
Epilepsy is a central nervous system (neurological) disorder in which brain activity becomes abnormal, causing seizures or periods of unusual behaviour, sensations, and sometimes loss of awareness. In China, reported estimates of the prevalence of active epilepsy vary from 0.48 to 8.51 per 1,00,000. While the estimated incidence rate is between 0.22 to 0.29 per 1,00,000. In China, it is estimated that there are approximately 9 million patients with epilepsy, approximately 60% of whom are affected by partial-onset seizures.
China is a growing market for rare epilepsies due to factors such as rise in the China’s incidence rate of epilepsy (0.22 to 0.29 per 1,00,000). In addition to this the other factors that contribute to the growth of the market are rise in healthcare expenditure, increase in awareness and availability of cost-effective treatments. In China it was estimated that the number of people with epilepsy in China is almost 9 million with a treatment gap of 63%. This cost-effective approach was successful in reducing the treatment gap by about 13%.
However, there are some restraining factors for the growth of the rare epilepsy’s therapeutics market in China such as lack of proper healthcare infrastructure in rural areas and also due to the social stigma attached to the disorder.